Tesamorelin + Ipamorelin vs Ipamorelin

Tesamorelin + Ipamorelin wins for:

• Maximizing IGF-1 elevation and visceral fat (VAT) reduction; the Phase III literature uniquely supports tesamorelin as a VAT-cutting tool.
• Synergistic, larger GH pulse (GHRH + GHRP acting at both pituitary and hypothalamus) for users chasing peak efficacy on recomp, recovery, and advanced anti-aging/longevity goals.
• Driving the greatest difference vs baseline in midsection aesthetics and lean-mass retention during hard cuts or on GLP-1 analogs.

Ipamorelin wins for:

• Simplicity, lower cost, and accessible protocols for those who want sharper sleep, joint support, or a mild and clean boost to endogenous GH/IGF-1 without extra logistics.
• Minimal side effect profile and easier sourcing—no lyophilized GHRH analog to reconstitute or stealth-ship.
• Lower risk of injection-site reactions, fluid retention, and no protocol complexity—just fasted subQ or pre-bed dosing.

Pick Tesamorelin + Ipamorelin if:

• VAT reduction and improvement in midsection aesthetics is a lead goal (especially for physique competitors, anyone prepping for a cut, or longevity-focused stacks).
• The protocol calls for maximum IGF-1 increase without exogenous HGH, while sparing subQ fat and minimizing water retention.
• The recovery stack is layered with other advanced agents (TRT, GLP-1s) and demands strong joint, tendon, and sleep benefits.
• There's a willingness to work with a more complex protocol (reconstitution, cold chain, coordinated timing, sourcing from higher-end peptide labs).
• Bloodwork monitoring and fine-tuning for IGF-1 is prioritized, and budget/commitment matches.

Pick Ipamorelin if:

• The goal is a clean, safe bump to endogenous GH, targeting recovery, sleep, tendon health, or modest recomp with easy daily protocols.
• Stacking with GHRH analogs (CJC-1295, mod-GRF(1-29)) isn't planned; solo ipamorelin is sufficient for the outcomes targeted.
• Cost, simplicity, and minimal protocol management are deciding factors; fewer moving parts are preferred.
• Past protocols caused issues with cortisol/prolactin elevation, or users require the lowest possible side-effect risk.
• There is no interest in complex stacking, or cold chain is a dealbreaker for logistics or sourcing.